Coumarin use in dialysis patients with atrial fibrillation: Yes, after individual risk stratification (Nephrol Dial Transplant (2009) DOI: 10.1093/ndt/gfp385);Coumarin use in dialysis patients with arterial fibrillation: Yes, after individual risk stratification

Nephrology Dialysis Transplantation

Volumn 24, Issue 11, 2009, Pages 3285-3287

  Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atrial fibrillation; Haemodialysis; Warfarin

Indexed keywords

COUMARIN; ANTICOAGULANT AGENT; COUMARIN DERIVATIVE;

BLOOD VESSEL CALCIFICATION; CEREBROVASCULAR ACCIDENT; ELECTROLYTE DISTURBANCE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEMODIALYSIS; HEREDITY; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SHORT SURVEY; SURVIVAL RATE; SYMPATHETIC TONE; ARTICLE; CHRONIC KIDNEY FAILURE; RENAL REPLACEMENT THERAPY; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COUMARINS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; STROKE;

EID: 73949129313     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp636     Document Type: Erratum

References (14)

1. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711
2. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int 2009; [Epub ahead of print]
3. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 2006
4. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis 2008; 51: 255-262
5. Vázquez E, Sánchez-Perales C, Lozano C, et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol 2003; 92: 868-871
6. Quinn RR, Naimark DM, Oliver MJ, et al. Should hemodialysis patients with atrial fibrillation undergo systemic anticoagulation? A cost-utility analysis. Am J Kidney Dis 2007; 50: 421-432
7. To AC, Yehia M, Collins JF. Atrial fibrillation in haemodialysis patients: do the guidelines for anticoagulation apply? Nephrology (Carl-ton) 2007; 12: 441-447
8. Bennett WM. Should dialysis patients ever receive warfarin and for what reasons? Clin J Am Soc Nephrol 2006; 1: 1357-1359
9. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-921
10. Chan KE, Lazarus JM, Thadhani R, et al. Anticoagulant and an-tiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 2009; 20: 872-881
11. Danziger J. Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 2008; 3: 1504-1510
12. Lo DS, Rabbat CG, Clase CM. Thromboembolism and anticoagulant management in hemodialysis patients: a practical guide to clinical management. Thromb Res 2006; 118: 385-395
13. Dahri K, Loewen P. The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules. Thromb Haemost 2007; 98: 980-987
14. Aronow WS. Acute and chronic management of atrial fibrillation in patients with late-stage CKD. Am J Kidney Dis 2009; 53: 701-710